PROZAC CAPSULES 20MG

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

FLUOXETINE (FLUOXETINE HYDROCHLORIDE)

Inapatikana kutoka:

ELI LILLY CANADA INC

ATC kanuni:

N06AB03

INN (Jina la Kimataifa):

FLUOXETINE

Kipimo:

20MG

Dawa fomu:

CAPSULE

Tungo:

FLUOXETINE (FLUOXETINE HYDROCHLORIDE) 20MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

100CAP

Dawa ya aina:

Prescription

Eneo la matibabu:

SELECTIVE-SEROTONIN REUPTAKE INHIBITORS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0116847001; AHFS:

Idhini hali ya:

MARKETED

Idhini ya tarehe:

1989-12-31

Tabia za bidhaa

_PROZAC_ _(fluoxetine hydrochloride) _
_Page 1 of 53_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
PROZAC
®
fluoxetine hydrochloride
Capsules, 10 mg and 20 mg (equivalent to Fluoxetine), Oral
Antidepressant / Antiobsessional / Antibulimic
© Eli Lilly Canada Inc.
Exchange Tower
130 King Street West, Suite 900
PO Box 73
Toronto, Ontario
M5X 1B1
1-888-545-5972
www.lilly.ca
Date of Initial Authorization:
DEC 31,1989
Date of Revision:
JAN 12, 2024
Submission Control Number: 277882
_PROZAC (fluoxetine hydrochloride) _
_Page 2 of 53_
RECENT MAJOR LABEL CHANGES
7 Warnings and Precautions, Neurologic
01/2024
7 Warnings and Precautions, Reproductive Health: Female and
Male Potential
01/2024
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNING AND PRECAUTIONS BOX
.............................................................. 5
4
DOSAGE AND ADMINISTRATION
.................................................................................
6
4.1
Dosing Considerations
............................................................................................
6
4.2
Recommended Do